COPD-ST2OP was a single-centre, double-blind, placebo- controlled, parallel group, randomised controlled trial to assess the efficacy and safety of anti-ST2 compared to placebo, in patients with moderate to very severe COPD. This evidence concerns the gene IL1RL1 and chronic obstructive pulmonary disease.